Anzeige
Meldung des Tages: Game Changer! Steht hier jetzt die strukturelle Neubewertung nach einem Strategiewechsel bevor?

Vanda Pharmaceuticals Aktie News

Aktie
WKN:  A0JJT3 ISIN:  US9216591084 US-Symbol:  VNDA Branche:  Biotechnologie Land:  USA
6,40 €
-0,15 €
-2,29%
13:14:14 Uhr
Depot/Watchlist
Marktkapitalisierung *
348,72 Mio. €
Streubesitz
14,40%
KGV
-14,97
Index-Zuordnung
-

Vanda Pharmaceuticals News

22.01.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA PR Newswire
15.01.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA PR Newswire
08.01.26 - PR Newswire
Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder
Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder PR Newswire
30.12.25 - PR Newswire
Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness
Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion ...
15.12.25 - PR Newswire
Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis PR Newswire
11.12.25 - PR Newswire
Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference PR Newswire
04.12.25 - PR Newswire
FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness
FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness PR Newswire
28.11.25 - PR Newswire
Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness
Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness PR Newswire
17.11.25 - PR Newswire
Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting
Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting PR Newswire
05.11.25 - PR Newswire
Vanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference
Vanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference PR Newswire
29.10.25 - PR Newswire
Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results
Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results PR Newswire
22.10.25 - PR Newswire
Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025
Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025 PR Newswire
08.10.25 - PR Newswire
Monumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena
Monumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena PR Newswire
01.10.25 - PR Newswire
Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration
Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration PR Newswire
25.09.25 - PR Newswire
Vanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial"
Vanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A ...
28.08.25 - PR Newswire
Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences
Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences PR Newswire
28.08.25 - PR Newswire
Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera
Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera PR Newswire
18.08.25 - PR Newswire
In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder
In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder PR Newswire
31.07.25 - PR Newswire
Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results
Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results PR Newswire
23.07.25 - PR Newswire
Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025
Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025 PR Newswire

Newssuche

Videos

newspaper
13:00 Uhr +2,27%
Technical Trading: Pfund Short
GBP/USD Short Typ: Turbo Open End WKN: VH3A2E Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »